Aptose Initiates Dosing of CG-806 in Patients with Acute Myeloid Leukemia
19 oct. 2020 07h00 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
Aptose Announces FDA Allowance of IND for Phase 1a/b Study of CG-806 in Acute Myeloid Leukemia
29 juin 2020 07h01 HE
|
Aptose Biosciences, Inc.
Oral FLT3/BTK inhibitor CG-806 expands development beyond B-cell malignancies to the treatment of AML Phase 1a/b study in B-cell malignancies continues through dose escalation SAN DIEGO and TORONTO,...
Aptose Presents Early Phase 1a/b CG-806 Clinical Findings at the 25th Congress of the European Hematology Association
12 juin 2020 07h00 HE
|
Aptose Biosciences, Inc.
Safety, tolerability and phospho-BTK inhibition at first three CG-806 dose levels in patients with CLL and other B-cell malignancies Plasma from CG-806 treated patients completely inhibited...
Aptose Presents Preliminary Clinical Data on CG-806 at AACR Virtual Annual Meeting 2020
27 avr. 2020 09h00 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, April 27, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Reports Results for the Fourth Quarter and Full Year 2019
10 mars 2020 16h02 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 10, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
Aptose to Participate at 5th International Conference on Acute Myeloid Leukemia of the European School of Haematology (ESH)
10 oct. 2019 07h30 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
Aptose Doses First CLL Patient in Phase 1 Study of CG-806 and Doses Third Cohort in Phase 1 Study of APTO-253
16 juil. 2019 07h05 HE
|
Aptose Biosciences, Inc.
– CG-806 oral non-covalent pan-FLT3/pan-BTK inhibitor being developed for the treatment of CLL and other B-cell malignancies and for AML – – APTO-253 MYC inhibitor being developed for the...
Aptose Presents New Preclinical Data for CG-806 at the 24th Congress of the European Hematology Association
14 juin 2019 07h00 HE
|
Aptose Biosciences, Inc.
– CG-806 safely and durably suppressed tumor growth in preclinical models – SAN DIEGO and TORONTO, June 14, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:...
Aptose Presents New Preclinical Data on CG-806 and APTO-253 at the 2019 AACR Annual Meeting
01 avr. 2019 13h00 HE
|
Aptose Biosciences, Inc.
Pan-FLT3/pan-BTK inhibitor CG-806 Demonstrates Significant and Superior Potency Against Primary Cells Across AML Types – MYC Inhibitor APTO-253 Potently Kills Hematologic Cell Lines; Mechanism of...
Aptose Announces FDA Allowance of Investigational New Drug Application for CG-806
25 mars 2019 07h02 HE
|
Aptose Biosciences, Inc.
– CG-806 highly potent, oral, non-covalent pan-FLT3/pan-BTK inhibitor being developed for the treatment of CLL and other B-cell malignancies and for AML – – Phase 1 trial in relapsed or refractory...